A.I. Burnasyan FMBC clinical bulletin. 2023 № 2
V.F. Levshin3, O.F. Serova1,2, N.V. Shutikova1,2, L.V. Sedaya1,2
Breast Cancer Associated with Pregnancy
1GBUZ MO “Moscow Regional Perinatal Center”, Moscow region
2A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
3FSBI “National Medical Research Center of Oncology named after N.N. Blokhin” of the Ministry of Health of the Russian Federation, Moscow, Russia
Contact person: Shutikova Natalya Vyacheslavovna: omo_2012@mail.ru
Abstract
Pregnancy-associated breast cancer (PMGAB) is most commonly defined as breast cancer (BC) diagnosed during pregnancy or ≤1 year postpartum. In clinical practice, BCAA is relatively rare, but in recent years the number of such cases has increased due to an increase in the average age at birth and an increase in the overall incidence of breast cancer. Clinical observations show a certain variety of clinical and pathological features and prognosis in BCAA. A description is given of our own observations of three cases of BCAA, 2 cases detected during pregnancy and one during lactation. A review of studies of cases of BCAA in different populations was carried out. Most studies of RMJAB have established a worse prognosis for this form of breast cancer, primarily associated. with later diagnosis, which in turn is associated with the difficulty of early diagnosis of breast cancer during pregnancy and lactation.
Studies show that PMFA is a clinically heterogeneous group of patients for whom both the subtype of breast cancer and at what gestational age a tumor in the mammary gland is detected should be taken into account when determining the treatment plan and prognosis of breast cancer. Further research is needed in RMJAB in order to determine the biological mechanisms of the action of pregnancy at different times on the mammary gland at the cellular and molecular level. It is important to distinguish between changes associated with pregnancy, which reduce and which increase the risk of breast cancer.
Keywords: pregnancy-associated breast cancer, clinical and pathological characteristics, prognosis, algorithm for managing and treating patients
For citation: Levshin VF, Serova OF, Shutikova NV, Sedaya LV. Breast Cancer Associated with Pregnancy. Review. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.2:23-27. (In Russian) DOI: 10.33266/2782-6430-2023-2-23-27
REFERENCES
1. Даниличев В.Ф. Обоснование и эффективность применения протеолитических ферментов при патологии глаз (клинико-экспериментальное исследование): Автореф. дис. … д-ра мед. наук. 1983. С. 24.
2. Oh J.O., Minasi P., Grabner G., Ohashi Y. Suppression of Secondary Herpes Simplex Uveitis by Cyclosporine // Invest. Ophthalmol. Vis. Sci. 1985. V.26, No. 4. P. 494-500.
3. Brown C.A. Penicillin in Ophthalmology: The Bacteriological, Experimental, and Clinical Evidence of Its Value, Including a Personal Series of 125 Clinical Cases // Br. J. Ophthalmol. 1946. V.30, No. 3. P. 146-167.
4. Sorsby A., Ungar J. Intravitreal Injection of Penicillin; Study on the Levels of Concentration Reached and Therapeutic Efficacy // Br. J. Ophthalmol. 1948. V.32, No. 12. P. 857-864. DOI:10.1136/bjo.32.12.857.
5. Воронин Г.В., Будзинская М.В., Страховская М.Г., Халатян А.С. Резистентность к антибиотикам у пациентов на фоне многократных интравитреальных инъекций // Вестник Офтальмологии. 2019. № 3. С. 109-112.
6. Yin V.T., Weisbrod D.J., Eng K.T., et al. Antibiotic Resistance of Ocular Surface Flora with Repeated Use of a Topical Antibiotic after Intravitreal Injection // JAMA Ophthalmol. 2013. V.131, No. 4. P. 456-461. DOI:10.1001/jamaophthalmol.2013.2379.
7. Miño De Kaspar H., Hoepfner A.S., Engelbert M., et al. Antibiotic Resistance Pattern and Visual Outcome in Experimentally-Induced Staphylococcus Epidermidis Endophthalmitis in a Rabbit Model // Ophthalmology. 2001. V.108, No. 3. P. 470-478. DOI:10.1016/s0161-6420(00)00545-5.
8. Benoist d’Azy C., Pereira B., Naughton G., Chiambaretta F., Dutheil F. Antibioprophylaxis in Prevention of Endophthalmitis in Intravitreal Injection: A Systematic Review and Meta-Analysis // PLoS One. 2016. V.11, No. 6. P. e0156431. DOI:10.1371/journal.pone.0156431.
9. Ferguson A.W., Scott J.A., McGavigan J., et al. Comparison of 5% Povidone-Iodine Solution Against 1% Povidone-Iodine Solution in Preoperative Cataract Surgery Antisepsis: a Prospective Randomised Double Blind Study // Br. J. Ophthalmol. 2003. V.87, No. 2. P. 163-167. DOI:10.1136/bjo.87.2.163.
10. Deramo V.A., Lai J.C., Fastenberg D.M., Udell I.J. Acute Endophthalmitis in Eyes Treated Prophylactically with Gatifloxacin and Moxifloxacin // Am. J. Ophthalmol. 2006. V.142, No. 5. P. 721-725. DOI:10.1016/j.ajo.2006.05.044.
11. Miller D., Flynn P.M., Scott I.U., Alfonso E.C., Flynn H.W. Jr. In Vitro Fluoroquinolone Resistance in Staphylococcal Endophthalmitis Isolates // Arch. Ophthalmol. 2006. V.124, No. 4. P. 479-483. DOI:10.1001/archopht.124.4.479.
12. Pożarowska D., Pożarowski P. The Era of Anti-Vascular Endothelial Growth Factor (VEGF) Drugs in Ophthalmology, VEGF and Anti-VEGF Therapy // Cent. Eur. J. Immunol. 2016. V.41, No. 3. P. 311-316. DOI:10.5114/ceji.2016.63132.
13. Good T.J., Kimura A.E., Mandava N., Kahook M.Y. Sustained Elevation of Intraocular Pressure after Intravitreal Injections of Anti-VEGF Agents // Br. J. Ophthalmol. 2011. V.95, No. 8. P. 1111-1114. DOI:10.1136/bjo.2010.180729.
14. Mansour A.M., Shahin M., Kofoed P.K., et al. Insight Into 144 Patients with Ocular Vascular Events During VEGF Antagonist Injections // Clin. Ophthalmol. 2012. No. 6. P. 343-363. DOI:10.2147/OPTH.S29075.
15. SooHoo J.R., Seibold L.K., Kahook M.Y. The Link between Intravitreal Antivascular Endothelial Growth Factor Injections and Glaucoma // Curr. Opin. Ophthalmol. 2014. V.25, No. 2. P. 127-133. DOI:10.1097/ICU.0000000000000036.
16. Dedania V.S., Bakri S.J. Sustained Elevation of Intraocular Pressure after Intravitreal Anti-Vegf Agents: What Is the Evidence? // Retina. 2015. V.35, No. 5. P. 841-858. DOI:10.1097/IAE.0000000000000520.
17. Neely D.C., Bray K.J., Huisingh C.E., Clark M.E., McGwin G.Jr., Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care // JAMA Ophthalmol. 2017. V.135, No. 6. P. 570-575. DOI:10.1001/jamaophthalmol.2017.0830.
18. Brown D.M., Campochiaro P.A., Bhisitkul R.B., et al. Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study // Ophthalmology. 2011. V.118, No. 8. P. 1594-1602. DOI:10.1016/j.ophtha.2011.02.022.
19. Ciulla T.A., Huang F., Westby K., Williams D.F., Zaveri S., Patel S.C. Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States // Ophthalmol Retina. 2018. V.2, No. 7. P. 645-653. DOI:10.1016/j.oret.2018.01.006.
20. Aref A.A.. Management of Immediate and Sustained Intraocular Pressure Rise Associated with Intravitreal Antivascular Endothelial Growth Factor Injection Therapy // Curr. Opin. Ophthalmol. 2012. V.23, No. 2. P. 105-110. DOI:10.1097/ICU.0b013e32834ff41d.
21. Kiddee W., Montriwet M. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents // PLoS One. 2015. V.10, No. 9. P. e0137833. DOI:10.1371/journal.pone.0137833.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 28.02.2023. Accepted for publication: 22.03.2023